BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
India pharma market posted a higher decline of 4.8% YoY in April 2022 versus a 2% decline YoY in March 2022.
Adjusting for Covid-19 sales in April-21, the YoY growth has been 9.2% for April-22.
The contribution from Covid drugs remained healthy at 34% for April-22 as well.
Therapy-wise, anti-infectives/respiratory/vitamin-mineral-nutrient/cardiac dragged IPM with YoY declines of 37.2% /13.7%/9.8%/0.9% YoY, respectively.
Derma/gynaec/neuro/gastro therapies grew 18.7%/15.9%/10.7%/5.2% YoY, respectively, offsetting the decline to some extent.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
POPULAR